Literature DB >> 26663440

Diagnostic assays for polyomavirus JC and progressive multifocal leukoencephalopathy.

Martyn K White1, Ilker K Sariyer1, Jennifer Gordon1, Serena Delbue2, Valeria Pietropaolo3, Joseph R Berger4, Kamel Khalili1.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a devastating and often fatal demyelinating disease of the central nervous system for which effective therapies are lacking. It is caused by the replication of polyomavirus JC (JCV) in the oligodendrocytes and astrocytes leading to their cytolytic death and loss of myelin from the subcortical white matter. While the virus is very common in human populations worldwide, the incidence of the disease is very low and confined almost exclusively to individuals with some form of immunological dysfunction. However, the number of people who constitute the at-risk population is growing larger and includes individuals with HIV-1/AIDS and patients receiving immunomodulatory therapies such as multiple sclerosis patients treated with natalizumab. Further adding to the public health significance of this disease are the difficulties encountered in the diagnosis of PML and the lack of useful biomarkers for PML progression. In this review, we examine the diagnostic assays that are available for different aspects of the JCV life cycle, their usefulness and drawbacks, and the prospects for improvements.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26663440      PMCID: PMC4883008          DOI: 10.1002/rmv.1866

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  92 in total

Review 1.  Progressive multifocal leukoencephalopathy: clinical and molecular aspects.

Authors:  Eleonora Tavazzi; Martyn K White; Kamel Khalili
Journal:  Rev Med Virol       Date:  2011-09-21       Impact factor: 6.989

2.  Detection of polyoma virus DNA in PML-brain tissue by (in situ) hybridization.

Authors:  K Dörries; R T Johnson; V ter Meulen
Journal:  J Gen Virol       Date:  1979-01       Impact factor: 3.891

3.  JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy.

Authors:  I J Koralnik; R A Du Pasquier; N L Letvin
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

4.  Comparison of antibody titers determined by hemagglutination inhibition and enzyme immunoassay for JC virus and BK virus.

Authors:  R S Hamilton; M Gravell; E O Major
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

Review 5.  HIV disorders of the brain: pathology and pathogenesis.

Authors:  Luis Del Valle; Sergio Piña-Oviedo
Journal:  Front Biosci       Date:  2006-01-01

6.  SV40-encoded microRNAs regulate viral gene expression and reduce susceptibility to cytotoxic T cells.

Authors:  Christopher S Sullivan; Adam T Grundhoff; Satvir Tevethia; James M Pipas; Don Ganem
Journal:  Nature       Date:  2005-06-02       Impact factor: 49.962

7.  Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient.

Authors:  F Bernal-Cano; J T Joseph; I J Koralnik
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

8.  JC virus antibody status underestimates infection rates.

Authors:  Joseph R Berger; Sidney A Houff; Julie Gurwell; Nubia Vega; Craig S Miller; Robert J Danaher
Journal:  Ann Neurol       Date:  2013-08-06       Impact factor: 10.422

9.  Expression of JC virus agnoprotein in progressive multifocal leukoencephalopathy brain.

Authors:  Yuki Okada; Hirofumi Sawa; Shuichi Endo; Yasuko Orba; Takashi Umemura; Hiroshi Nishihara; Alexandru C Stan; Shinya Tanaka; Hidehiro Takahashi; Kazuo Nagashima
Journal:  Acta Neuropathol       Date:  2002-05-24       Impact factor: 17.088

Review 10.  Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab.

Authors:  Caroline Antoniol; Bruno Stankoff
Journal:  Front Immunol       Date:  2015-01-05       Impact factor: 7.561

View more
  8 in total

1.  JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab.

Authors:  Elena Uleri; Gabriele Ibba; Claudia Piu; Maurizio Caocci; Stefania Leoni; Giannina Arru; Caterina Serra; GianPietro Sechi; Antonina Dolei
Journal:  J Neurovirol       Date:  2016-11-03       Impact factor: 2.643

Review 2.  Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals.

Authors:  Deanna Saylor; Arun Venkatesan
Journal:  Curr Infect Dis Rep       Date:  2016-11       Impact factor: 3.725

3.  Early Pathological JC Virus Lesions in a Patient without Any MRI-based Indications.

Authors:  Nobuo Sanjo; Yurie Nose; Shouhei Miyamoto; Yukiko Shishido-Hara; Tatsuya Saito; Tetsuya Fukuda; Kurara Yamamoto; Daisuke Kobayashi; Takanori Yokota
Journal:  Intern Med       Date:  2020-11-09       Impact factor: 1.271

4.  The DNA damage response promotes polyomavirus JC infection by nucleus to cytoplasm NF- kappaB activation.

Authors:  Martyn K White; Anna Bellizzi; Gabriele Ibba; Valeria Pietropaolo; Anna T Palamara; Hassen S Wollebo
Journal:  Virol J       Date:  2017-02-15       Impact factor: 4.099

5.  Prevalence of DNA of fourteen human polyomaviruses determined in blood donors.

Authors:  Sergio Kamminga; Els van der Meijden; Caroline de Brouwer; Mariet Feltkamp; Hans Zaaijer
Journal:  Transfusion       Date:  2019-10-21       Impact factor: 3.157

6.  Targeted metabolomic profiling of cerebrospinal fluid from patients with progressive multifocal leukoencephalopathy.

Authors:  Yi Luo; Nora Möhn; Amani Al-Mekhlafi; Sven Schuchardt; Thomas Skripuletz; Wolfram Sühs; Frank Pessler; Martin Stangel
Journal:  PLoS One       Date:  2020-11-24       Impact factor: 3.240

Review 7.  Complexities of JC Polyomavirus Receptor-Dependent and -Independent Mechanisms of Infection.

Authors:  Jenna Morris-Love; Walter J Atwood
Journal:  Viruses       Date:  2022-05-24       Impact factor: 5.818

8.  Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment.

Authors:  Carla Prezioso; Marco Ciotti; Gabriele Brazzini; Francesca Piacentini; Sara Passerini; Alfonso Grimaldi; Doriana Landi; Carolina Gabri Nicoletti; Maria Antonella Zingaropoli; Marco Iannetta; Marta Altieri; Antonella Conte; Dolores Limongi; Girolama Alessandra Marfia; Maria Rosa Ciardi; Claudio Maria Mastroianni; Anna Teresa Palamara; Ugo Moens; Valeria Pietropaolo
Journal:  J Clin Med       Date:  2022-01-11       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.